The AABB website is currently experiencing technical issues related to login and SSO. Thank you for your patience as we work to get this resolved. If you need immediate assistance, please contact us.
The Cellular, Tissue and Gene Therapies Advisory Committee — formerly called the Biological Response Modifiers Advisory Committee — reviews and evaluates available data relating to the safety, effectiveness, and appropriate use of human cells, human tissues, gene transfer therapies, and xenotransplantation products that are intended for transplantation, implantation, infusion, and transfer in the prevention and treatment of a broad spectrum of human diseases and in the reconstruction, repair or replacement of tissues for various conditions. Members of the committee include authorities knowledgeable in the fields of cellular therapies, tissue transplantation, hematology/oncology, and human tissues and transplantation, among other specialties.
AABB is now the Association for the Advancement of Blood & Biotherapies. Learn more about our new name and brand – and watch as we evolve throughout 2022.
4550 Montgomery Avenue
Suite 700, North Tower
Bethesda, MD 20814
301.907.6977
AABB (Association for the Advancement of Blood & Biotherapies) is an international, not-for-profit organization representing individuals and institutions involved in the fields of transfusion medicine and biotherapies. The Association works collaboratively to advance the field through the development and delivery of standards, accreditation and education programs. AABB is dedicated to its mission of improving lives by making transfusion medicine and biotherapies safe, available and effective worldwide.
©2022 All Rights Reserved. AABB - Association for the Advancement of Blood & Biotherapies
Web Design and Development by Matrix Group International, Inc.